

Pregabalin Market By Type (Tablets and Capsules, Others), By Application (Epilepsy, Neuropathic Pain, Others), By Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2022 - 2032

<https://marketpublishers.com/r/PE0AD53A41BAEN.html>

Date: February 2024

Pages: 289

Price: US\$ 3,570.00 (Single User License)

ID: PE0AD53A41BAEN

Abstracts

The pregabalin market was valued at \$1.6 billion in 2022 and is estimated to reach \$2.2 billion by 2032, exhibiting a CAGR of 3% from 2023 to 2032. Pregabalin belongs to a group of drugs known as anticonvulsants or antiepileptic drugs. Epilepsy, anxiety disorder, and neuropathic pain are the main conditions that pregabalin treats majorly. It is a member of the class of medications known as gabapentinoids, which function in the brain by modifying the activity of specific neurotransmitters.

Pregabalin was first developed as an antiepileptic medication, then it was subsequently discovered to be useful in treating a number of neuropathic pain conditions, such as fibromyalgia, diabetic neuropathy, and postherpetic neuralgia (pain in the nerves after shingles). By binding to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, it reduces the release of neurotransmitters such as substance P, noradrenaline, and glutamate. This control over the release of neurotransmitters lessens the likelihood of pain and stabilizes aberrant electrical activity in the brain. Pregabalin is used as an antiepileptic drug to treat generalized anxiety disorder (GAD). It is believed to have an anxiolytic effect by inhibiting the release of neurotransmitters, including glutamate and norepinephrine that are involved in anxiety pathways.

The major factor that drives the market is the surge in prevalence of neuropathic pain.

Rise in geriatric population, an increase in the incidence of diabetes, and advancements in diagnostics have all contributed to a surge in the prevalence of neuropathic pain diseases, such as diabetic neuropathy and postherpetic neuralgia. Pregabalin is in high demand due to its efficacy in treating neuropathic pain, which is experienced by an increasing number of patients, thereby driving the growth of the market.

Epilepsy is a neurological illness marked by recurring seizures. Moreover, there is a surge in the incidence of epilepsy. More people receive epilepsy diagnoses and treatments as a result of greater healthcare accessibility and rise in awareness of the ailment. Patients with epilepsy are provided pregabalin, an antiepileptic treatment, to control their seizures, which increases demand for the drug, thus driving the market.

Furthermore, the rise in the number of individuals suffering from the anxiety fosters the consumption of pregabalin. With its approval for the management of GAD, the market potential of pregabalin has grown beyond the treatment of pain and epilepsy. The effectiveness of pregabalin in treating anxiety and the rise in public awareness of mental health issues are factors that drive the market expansion of this drug.

Moreover, peripheral edema, weight gain, sleepiness, and dizziness are among the side effects of pregabalin. The broad use of this medication is restricted due to safety concerns, namely pertaining to the possibility of misuse, dependence, and withdrawal symptoms. Moreover, pregabalin faces competition in the market from alternative treatments for neuropathic pain, epilepsy, and anxiety disorders, such as non-pharmacological therapies, physical therapy, and other pharmaceuticals. However, due to rise in patient population, increased disposable budgets, and improved access to healthcare, emerging markets offer pregabalin manufacturers unexplored prospects. Factors such as modifying price strategies, expanding distribution channels, and marketing initiatives are anticipated to drive market growth.

The pregabalin market is segmented into type, application, distribution channel, and region. On the basis of type, the market is bifurcated into tablet & capsules and others. On the basis of application, the market is classified into neuropathic pain, epilepsy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers.

On the basis of region, market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (India, China, Japan, Australia, South Korea, and rest of Asia-Pacific), and

Latin America (Brazil, Argentina, Colombia, and rest of Latin America), and Middle East & Africa (GCC, South Africa, North Africa, and rest of LAMEA).

The major players that operate in the pregabalin market include Viatrix Inc., Cipla, Amneal Pharmaceuticals, Rising Pharmaceutical, Teva Pharmaceutical, Lupin, ScieGen Pharmaceuticals Inc., Zydus, Medley Pharmaceuticals Ltd., and Novartis AG. The key players have adopted key strategies such as product launch to expand their product portfolio.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pregabalin market analysis from 2022 to 2032 to identify the prevailing pregabalin market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the pregabalin market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global pregabalin market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more):

Patient/epidemiology data at country, region, global level

Regulatory Guidelines

Additional company profiles with specific to client's interest

Additional country or region analysis- market size and forecast

Expanded list for Company Profiles

Historic market data

SWOT Analysis

Key Market Segments By Type Tablets and Capsules

Others

By Application Epilepsy

Neuropathic Pain

Others

By Distribution Channel Hospital Pharmacies

Drug Store and Retail Pharmacies

Online Providers

By Region

North America U.S.

Canada

Mexico

Europe Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

Latin America Brazil

Colombia

Argentina

Rest of Latin America

Middle East and Africa Gcc

South Africa

North Africa

Rest of Middle East And Africa

Key Market Players

Viartis Inc.

Rising Pharmaceuticals

Cipla

Lupin Pharmaceuticals

Teva Pharmaceutical Industries Ltd

Markans Pharma Ltd.

Sciegen Pharmaceuticals Inc.

Zydus Group

Novartis AG

Amneal Pharmaceuticals LLC

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
 - 1.4.1. Primary research
 - 1.4.2. Secondary research
 - 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
 - 3.2.1. Top impacting factors
 - 3.2.2. Top investment pockets
- 3.3. Porter s five forces analysis
 - 3.3.1. Low bargaining power of suppliers
 - 3.3.2. Low threat of substitutes
 - 3.3.3. Low threat of new entrants
 - 3.3.4. Moderate intensity of rivalry
 - 3.3.5. Low bargaining power of buyers
- 3.4. Market dynamics
 - 3.4.1. Drivers
 - 3.4.1.1. Rising prevalence of neuropathic pain, epilepsy, and anxiety disorders
 - 3.4.1.2. Growing geriatric population with higher incidence of chronic pain conditions
 - 3.4.1.3. Increased awareness and diagnosis of chronic neurological and psychological disorders
 - 3.4.2. Restraints
 - 3.4.2.1. Limited awareness or access in rural and underdeveloped regions
 - 3.4.3. Opportunities
 - 3.4.3.1. Growth Opportunities in Emerging Markets

CHAPTER 4: PREGABALIN MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Tablets and Capsules

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Others

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

CHAPTER 5: PREGABALIN MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Epilepsy

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Neuropathic Pain

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Others

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

CHAPTER 6: PREGABALIN MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital Pharmacies

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Drug Store and Retail Pharmacies

- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Providers
 - 6.4.1. Key market trends, growth factors and opportunities
 - 6.4.2. Market size and forecast, by region
 - 6.4.3. Market share analysis by country

CHAPTER 7: PREGABALIN MARKET, BY REGION

7.1. Overview

- 7.1.1. Market size and forecast By Region

7.2. North America

- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
 - 7.2.5.1. U.S.
 - 7.2.5.1.1. Market size and forecast, by Type
 - 7.2.5.1.2. Market size and forecast, by Application
 - 7.2.5.1.3. Market size and forecast, by Distribution Channel
 - 7.2.5.2. Canada
 - 7.2.5.2.1. Market size and forecast, by Type
 - 7.2.5.2.2. Market size and forecast, by Application
 - 7.2.5.2.3. Market size and forecast, by Distribution Channel
 - 7.2.5.3. Mexico
 - 7.2.5.3.1. Market size and forecast, by Type
 - 7.2.5.3.2. Market size and forecast, by Application
 - 7.2.5.3.3. Market size and forecast, by Distribution Channel

7.3. Europe

- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
 - 7.3.5.1. Germany
 - 7.3.5.1.1. Market size and forecast, by Type
 - 7.3.5.1.2. Market size and forecast, by Application

- 7.3.5.1.3. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
 - 7.3.5.2.1. Market size and forecast, by Type
 - 7.3.5.2.2. Market size and forecast, by Application
 - 7.3.5.2.3. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
 - 7.3.5.3.1. Market size and forecast, by Type
 - 7.3.5.3.2. Market size and forecast, by Application
 - 7.3.5.3.3. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
 - 7.3.5.4.1. Market size and forecast, by Type
 - 7.3.5.4.2. Market size and forecast, by Application
 - 7.3.5.4.3. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
 - 7.3.5.5.1. Market size and forecast, by Type
 - 7.3.5.5.2. Market size and forecast, by Application
 - 7.3.5.5.3. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
 - 7.3.5.6.1. Market size and forecast, by Type
 - 7.3.5.6.2. Market size and forecast, by Application
 - 7.3.5.6.3. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
 - 7.4.1. Key market trends, growth factors and opportunities
 - 7.4.2. Market size and forecast, by Type
 - 7.4.3. Market size and forecast, by Application
 - 7.4.4. Market size and forecast, by Distribution Channel
 - 7.4.5. Market size and forecast, by country
 - 7.4.5.1. Japan
 - 7.4.5.1.1. Market size and forecast, by Type
 - 7.4.5.1.2. Market size and forecast, by Application
 - 7.4.5.1.3. Market size and forecast, by Distribution Channel
 - 7.4.5.2. China
 - 7.4.5.2.1. Market size and forecast, by Type
 - 7.4.5.2.2. Market size and forecast, by Application
 - 7.4.5.2.3. Market size and forecast, by Distribution Channel
 - 7.4.5.3. India
 - 7.4.5.3.1. Market size and forecast, by Type
 - 7.4.5.3.2. Market size and forecast, by Application
 - 7.4.5.3.3. Market size and forecast, by Distribution Channel

7.4.5.4. Australia

7.4.5.4.1. Market size and forecast, by Type

7.4.5.4.2. Market size and forecast, by Application

7.4.5.4.3. Market size and forecast, by Distribution Channel

7.4.5.5. South Korea

7.4.5.5.1. Market size and forecast, by Type

7.4.5.5.2. Market size and forecast, by Application

7.4.5.5.3. Market size and forecast, by Distribution Channel

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Market size and forecast, by Type

7.4.5.6.2. Market size and forecast, by Application

7.4.5.6.3. Market size and forecast, by Distribution Channel

7.5. Latin America

7.5.1. Key market trends, growth factors and opportunities

7.5.2. Market size and forecast, by Type

7.5.3. Market size and forecast, by Application

7.5.4. Market size and forecast, by Distribution Channel

7.5.5. Market size and forecast, by country

7.5.5.1. Brazil

7.5.5.1.1. Market size and forecast, by Type

7.5.5.1.2. Market size and forecast, by Application

7.5.5.1.3. Market size and forecast, by Distribution Channel

7.5.5.2. Colombia

7.5.5.2.1. Market size and forecast, by Type

7.5.5.2.2. Market size and forecast, by Application

7.5.5.2.3. Market size and forecast, by Distribution Channel

7.5.5.3. Argentina

7.5.5.3.1. Market size and forecast, by Type

7.5.5.3.2. Market size and forecast, by Application

7.5.5.3.3. Market size and forecast, by Distribution Channel

7.5.5.4. Rest of Latin America

7.5.5.4.1. Market size and forecast, by Type

7.5.5.4.2. Market size and forecast, by Application

7.5.5.4.3. Market size and forecast, by Distribution Channel

7.6. Middle East and Africa

7.6.1. Key market trends, growth factors and opportunities

7.6.2. Market size and forecast, by Type

7.6.3. Market size and forecast, by Application

7.6.4. Market size and forecast, by Distribution Channel

7.6.5. Market size and forecast, by country

7.6.5.1. Gcc

7.6.5.1.1. Market size and forecast, by Type

7.6.5.1.2. Market size and forecast, by Application

7.6.5.1.3. Market size and forecast, by Distribution Channel

7.6.5.2. South Africa

7.6.5.2.1. Market size and forecast, by Type

7.6.5.2.2. Market size and forecast, by Application

7.6.5.2.3. Market size and forecast, by Distribution Channel

7.6.5.3. North Africa

7.6.5.3.1. Market size and forecast, by Type

7.6.5.3.2. Market size and forecast, by Application

7.6.5.3.3. Market size and forecast, by Distribution Channel

7.6.5.4. Rest of Middle East And Africa

7.6.5.4.1. Market size and forecast, by Type

7.6.5.4.2. Market size and forecast, by Application

7.6.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction

8.2. Top winning strategies

8.3. Product mapping of top 10 player

8.4. Competitive dashboard

8.5. Competitive heatmap

8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Viatris Inc.

9.1.1. Company overview

9.1.2. Key executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. Rising Pharmaceuticals

9.2.1. Company overview

- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Cipla
 - 9.3.1. Company overview
 - 9.3.2. Key executives
 - 9.3.3. Company snapshot
 - 9.3.4. Operating business segments
 - 9.3.5. Product portfolio
 - 9.3.6. Business performance
 - 9.3.7. Key strategic moves and developments
- 9.4. Lupin Ltd.
 - 9.4.1. Company overview
 - 9.4.2. Key executives
 - 9.4.3. Company snapshot
 - 9.4.4. Operating business segments
 - 9.4.5. Product portfolio
 - 9.4.6. Business performance
 - 9.4.7. Key strategic moves and developments
- 9.5. Teva Pharmaceutical Industries Ltd
 - 9.5.1. Company overview
 - 9.5.2. Key executives
 - 9.5.3. Company snapshot
 - 9.5.4. Operating business segments
 - 9.5.5. Product portfolio
 - 9.5.6. Business performance
 - 9.5.7. Key strategic moves and developments
- 9.6. Marksans Pharma Ltd.
 - 9.6.1. Company overview
 - 9.6.2. Key executives
 - 9.6.3. Company snapshot
 - 9.6.4. Operating business segments
 - 9.6.5. Product portfolio
 - 9.6.6. Business performance
 - 9.6.7. Key strategic moves and developments
- 9.7. Amneal Pharmaceuticals LLC

- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Pfizer Inc.
 - 9.8.1. Company overview
 - 9.8.2. Key executives
 - 9.8.3. Company snapshot
 - 9.8.4. Operating business segments
 - 9.8.5. Product portfolio
 - 9.8.6. Business performance
 - 9.8.7. Key strategic moves and developments
- 9.9. Sun Pharmaceutical Industries Ltd.
 - 9.9.1. Company overview
 - 9.9.2. Key executives
 - 9.9.3. Company snapshot
 - 9.9.4. Operating business segments
 - 9.9.5. Product portfolio
 - 9.9.6. Business performance
 - 9.9.7. Key strategic moves and developments
- 9.10. zydus
 - 9.10.1. Company overview
 - 9.10.2. Key executives
 - 9.10.3. Company snapshot
 - 9.10.4. Operating business segments
 - 9.10.5. Product portfolio
 - 9.10.6. Business performance
 - 9.10.7. Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 01. GLOBAL PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 02. PREGABALIN MARKET FOR TABLETS AND CAPSULES, BY REGION, 2022-2032 (\$MILLION)

TABLE 03. PREGABALIN MARKET FOR OTHERS, BY REGION, 2022-2032 (\$MILLION)

TABLE 04. GLOBAL PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 05. PREGABALIN MARKET FOR EPILEPSY, BY REGION, 2022-2032 (\$MILLION)

TABLE 06. PREGABALIN MARKET FOR NEUROPATHIC PAIN, BY REGION, 2022-2032 (\$MILLION)

TABLE 07. PREGABALIN MARKET FOR OTHERS, BY REGION, 2022-2032 (\$MILLION)

TABLE 08. GLOBAL PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 09. PREGABALIN MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 (\$MILLION)

TABLE 10. PREGABALIN MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 (\$MILLION)

TABLE 11. PREGABALIN MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 (\$MILLION)

TABLE 12. PREGABALIN MARKET, BY REGION, 2022-2032 (\$MILLION)

TABLE 13. NORTH AMERICA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 14. NORTH AMERICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 15. NORTH AMERICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 16. NORTH AMERICA PREGABALIN MARKET, BY COUNTRY, 2022-2032 (\$MILLION)

TABLE 17. U.S. PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 18. U.S. PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 19. U.S. PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 20. CANADA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 21. CANADA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 22. CANADA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 23. MEXICO PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 24. MEXICO PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 25. MEXICO PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 26. EUROPE PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 27. EUROPE PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 28. EUROPE PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 29. EUROPE PREGABALIN MARKET, BY COUNTRY, 2022-2032 (\$MILLION)

TABLE 30. GERMANY PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 31. GERMANY PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 32. GERMANY PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 33. FRANCE PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 34. FRANCE PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 35. FRANCE PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 36. UK PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 37. UK PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 38. UK PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 39. ITALY PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 40. ITALY PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 41. ITALY PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 42. SPAIN PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 43. SPAIN PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 44. SPAIN PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 45. REST OF EUROPE PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

- TABLE 46. REST OF EUROPE PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 47. REST OF EUROPE PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 48. ASIA-PACIFIC PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 49. ASIA-PACIFIC PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 50. ASIA-PACIFIC PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 51. ASIA-PACIFIC PREGABALIN MARKET, BY COUNTRY, 2022-2032 (\$MILLION)
- TABLE 52. JAPAN PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 53. JAPAN PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 54. JAPAN PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 55. CHINA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 56. CHINA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 57. CHINA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 58. INDIA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 59. INDIA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 60. INDIA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 61. AUSTRALIA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 62. AUSTRALIA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 63. AUSTRALIA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 64. SOUTH KOREA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 65. SOUTH KOREA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 66. SOUTH KOREA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 67. REST OF ASIA-PACIFIC PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 68. REST OF ASIA-PACIFIC PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 69. REST OF ASIA-PACIFIC PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 70. LATIN AMERICA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 71. LATIN AMERICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 72. LATIN AMERICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 73. LATIN AMERICA PREGABALIN MARKET, BY COUNTRY, 2022-2032 (\$MILLION)

TABLE 74. BRAZIL PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 75. BRAZIL PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 76. BRAZIL PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 77. COLOMBIA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 78. COLOMBIA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 79. COLOMBIA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 80. ARGENTINA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 81. ARGENTINA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 82. ARGENTINA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 83. REST OF LATIN AMERICA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 84. REST OF LATIN AMERICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 85. REST OF LATIN AMERICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 86. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)

TABLE 87. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)

TABLE 88. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)

TABLE 89. MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY COUNTRY, 2022-2032 (\$MILLION)

- TABLE 90. GCC PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 91. GCC PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 92. GCC PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 93. SOUTH AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 94. SOUTH AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 95. SOUTH AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 96. NORTH AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 97. NORTH AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 98. NORTH AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 99. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY TYPE, 2022-2032 (\$MILLION)
- TABLE 100. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY APPLICATION, 2022-2032 (\$MILLION)
- TABLE 101. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 (\$MILLION)
- TABLE 102. VIATRIS INC.: KEY EXECUTIVES
- TABLE 103. VIATRIS INC.: COMPANY SNAPSHOT
- TABLE 104. VIATRIS INC.: PRODUCT SEGMENTS
- TABLE 105. VIATRIS INC.: SERVICE SEGMENTS
- TABLE 106. VIATRIS INC.: PRODUCT PORTFOLIO
- TABLE 107. VIATRIS INC.: KEY STRATERGIES
- TABLE 108. RISING PHARMACEUTICALS: KEY EXECUTIVES
- TABLE 109. RISING PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 110. RISING PHARMACEUTICALS: PRODUCT SEGMENTS
- TABLE 111. RISING PHARMACEUTICALS: SERVICE SEGMENTS
- TABLE 112. RISING PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 113. RISING PHARMACEUTICALS: KEY STRATERGIES
- TABLE 114. CIPLA: KEY EXECUTIVES
- TABLE 115. CIPLA: COMPANY SNAPSHOT
- TABLE 116. CIPLA: PRODUCT SEGMENTS
- TABLE 117. CIPLA: SERVICE SEGMENTS
- TABLE 118. CIPLA: PRODUCT PORTFOLIO

TABLE 119. CIPLA: KEY STRATEGIES

TABLE 120. LUPIN LTD.: KEY EXECUTIVES

TABLE 121. LUPIN LTD.: COMPANY SNAPSHOT

TABLE 122. LUPIN LTD.: PRODUCT SEGMENTS

TABLE 123. LUPIN LTD.: SERVICE SEGMENTS

TABLE 124. LUPIN LTD.: PRODUCT PORTFOLIO

TABLE 125. LUPIN LTD.: KEY STRATEGIES

TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES

TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT

TABLE 128. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS

TABLE 129. TEVA PHARMACEUTICAL INDUSTRIES LTD: SERVICE SEGMENTS

TABLE 130. TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO

TABLE 131. TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY STRATEGIES

TABLE 132. MARKSANS PHARMA LTD.: KEY EXECUTIVES

TABLE 133. MARKSANS PHARMA LTD.: COMPANY SNAPSHOT

TABLE 134. MARKSANS PHARMA LTD.: PRODUCT SEGMENTS

TABLE 135. MARKSANS PHARMA LTD.: SERVICE SEGMENTS

TABLE 136. MARKSANS PHARMA LTD.: PRODUCT PORTFOLIO

TABLE 137. MARKSANS PHARMA LTD.: KEY STRATEGIES

TABLE 138. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES

TABLE 139. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT

TABLE 140. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS

TABLE 141. AMNEAL PHARMACEUTICALS LLC: SERVICE SEGMENTS

TABLE 142. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO

TABLE 143. AMNEAL PHARMACEUTICALS LLC: KEY STRATEGIES

TABLE 144. PFIZER INC.: KEY EXECUTIVES

TABLE 145. PFIZER INC.: COMPANY SNAPSHOT

TABLE 146. PFIZER INC.: PRODUCT SEGMENTS

TABLE 147. PFIZER INC.: SERVICE SEGMENTS

TABLE 148. PFIZER INC.: PRODUCT PORTFOLIO

TABLE 149. PFIZER INC.: KEY STRATEGIES

TABLE 150. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES

TABLE 151. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 152. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS

TABLE 153. SUN PHARMACEUTICAL INDUSTRIES LTD.: SERVICE SEGMENTS

TABLE 154. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 155. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIES

TABLE 156. ZYDUS: KEY EXECUTIVES

TABLE 157. ZYDUS: COMPANY SNAPSHOT

TABLE 158. ZYDUS: PRODUCT SEGMENTS
TABLE 159. ZYDUS: SERVICE SEGMENTS
TABLE 160. ZYDUS: PRODUCT PORTFOLIO
TABLE 161. ZYDUS: KEY STRATEGIES

List Of Figures

LIST OF FIGURES

- FIGURE 01. PREGABALIN MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF PREGABALIN MARKET, 2022-2032
- FIGURE 03. TOP IMPACTING FACTORS IN PREGABALIN MARKET (2022 TO 2032)
- FIGURE 04. TOP INVESTMENT POCKETS IN PREGABALIN MARKET (2023-2032)
- FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 06. LOW THREAT OF SUBSTITUTES
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. MODERATE INTENSITY OF RIVALRY
- FIGURE 09. LOW BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL PREGABALIN MARKET: DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. PREGABALIN MARKET, BY TYPE, 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR TABLETS AND CAPSULES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. PREGABALIN MARKET, BY APPLICATION, 2022 AND 2032(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR EPILEPSY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR NEUROPATHIC PAIN, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. PREGABALIN MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PREGABALIN MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 22. PREGABALIN MARKET BY REGION, 2022 AND 2032(%)
- FIGURE 23. U.S. PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 24. CANADA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 25. MEXICO PREGABALIN MARKET, 2022-2032 (\$MILLION)

- FIGURE 26. GERMANY PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 27. FRANCE PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 28. UK PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 29. ITALY PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 30. SPAIN PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 31. REST OF EUROPE PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 32. JAPAN PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 33. CHINA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 34. INDIA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 35. AUSTRALIA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 36. SOUTH KOREA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 37. REST OF ASIA-PACIFIC PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 38. BRAZIL PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 39. COLOMBIA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 40. ARGENTINA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 41. REST OF LATIN AMERICA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 42. GCC PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 43. SOUTH AFRICA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 44. NORTH AFRICA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 45. REST OF MIDDLE EAST AND AFRICA PREGABALIN MARKET, 2022-2032 (\$MILLION)
- FIGURE 46. TOP WINNING STRATEGIES, BY YEAR (2022-2022)
- FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT (2022-2022)
- FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY (2022-2022)
- FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 50. COMPETITIVE DASHBOARD
- FIGURE 51. COMPETITIVE HEATMAP: PREGABALIN MARKET
- FIGURE 52. TOP PLAYER POSITIONING, 2022

I would like to order

Product name: Pregabalin Market By Type (Tablets and Capsules, Others), By Application (Epilepsy, Neuropathic Pain, Others), By Distribution Channel (Hospital Pharmacies, Drug Store and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2022 - 2032

Product link: <https://marketpublishers.com/r/PE0AD53A41BAEN.html>

Price: US\$ 3,570.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PE0AD53A41BAEN.html>